This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Federal Court Strikes Down Blue Cross Of Michigan's Denial Of Applied Behavior Analysis Therapy To Children With Autism

According to the suit, ABA therapy is a medically and scientifically accepted treatment that enables children with autism to increase communication, motor, and reasoning skills; enhance social functioning; decrease negative behaviors; and lead more independent lives.  The U.S. Surgeon General, the National Institutes of Health, the American Academy of Pediatrics, the Medicare and Medicaid systems, and leading scholars and researchers have all found ABA therapy to be effective in treating autism spectrum disorder. 

The evidence also shows that denying or delaying treatment can have profound negative consequences to the children.  Denial of therapy forever destroys the potential of these children to live full and independent lives.

Despite this evidence, Blue Cross has for years characterized ABA therapy as "experimental" and refused coverage to all children with autism.  It was this characterization and denial of coverage for ABA therapy that the federal court in Detroit struck down as illegal.

This ruling comes on the heels of another victory by the same law firms who litigated Berge, et al. v. United States of America, et al., Case No. 10-00373 (D.D.C., Hon. Reggie B. Walton), in which over 20,000 military families successfully sued the Department of Defense and Tricare for their denial of coverage for ABA therapy on similar grounds.

The attorneys for the Plaintiff families in Potter v. Blue Cross are:

Gerard V. Mantese, Esq. Brian M. Saxe, Esq.Mantese Honigman Rossman and Williamson, P.C.1361 E. Big Beaver Road Troy, Michigan 48083248-457-9200 Office248-515-6419 Cell

John J. Conway, Esq. John J. Conway P.C.26622 Woodward Ave., Suite 225 Royal Oak, Michigan 48067313-961-6525   Office313-574-2148   Cell

SOURCE Mantese Honigman Rossman and Williamson, P.C.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.69 -0.59%
FB $119.49 1.40%
GOOG $711.11 1.40%
YHOO $37.23 0.79%
TSLA $214.84 1.60%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs